June 9, 2003

Duration of Anticoagulation in Venous Thromboembolism

Author Affiliations

Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Intern Med. 2003;163(11):1265-1266. doi:10.1001/archinte.163.11.1265

ORAL ANTICOAGULATION with a vitamin K (phytonadione) antagonist has always been a problematic therapy. The risk of serious bleeding is substantial (2%-3% yearly) and does not decrease over time. In fact, as patients undergoing long-term therapy age, the bleeding risk increases. The therapeutic effect of oral anticoagulation falls in a narrow range between increased risk of thrombosis when the international normalized ratio (INR) is too low and increased bleeding risk when it is too high.

First Page Preview View Large
First page PDF preview
First page PDF preview